FORMULATION, OPTIMIZATION, AND EVALUATION OF SITAGLIPTIN AND SIMVASTATIN RAPIDLY DISSOLVING TABLETS by Bayoumi, Asmaa A.
 
 
FORMULATION, OPTIMIZATION, AND EVALUATION OF SITAGLIPTIN AND SIMVASTATIN 
RAPIDLY DISSOLVING TABLETS 
Original Article 
 
ASMAA A. BAYOUMI 
Pharmacy Department, Ibn Hayyan University College, Karbala, Iraq 
Email: asmaa.bayoumi79@gmail.com 
Received: 26 Jun 2018, Revised and Accepted: 14 Aug 2018 
ABSTRACT 
Objective: The scope of this work was to formulate sitagliptin and simvastatin rapidly dissolving tablets. However, simvastatin is practically 
insoluble in water. For improving its poor oral bioavailability and with the aim of facilitating administration to patients facing problems with 
swallowing rapidly dissolving tablets were prepared 
Methods: Tablets were prepared using superdisintegrant addition technique using croscarmellose sodium (Ac-di-sol), sodium starch glycolate 
(explotab) and crospovidone in different percentages. Evaluation tests such as weight variation, thickness, and content variation, and friability, 
disintegration, wetting time, in vitro dispersion and in vitro dissolution were carried out. 
Results: The results showed that the presence of crospovidone could enhance the dissolution rate of simvastatin greatly. The best-optimized 
formulae found were that F8, F9, and F10 which showed good disintegration and the dissolution rate of simvastatin and sitagliptin was more than 
90% after 10 min while the dissolution rate for simvastatin and sitagliptin pure standards was 12% and 30%, respectively after 10 min. 
Conclusion: Some tablet formulae showed acceptable pharmacotechnical properties and complied with compendium requirements. Results of 
dissolution studies revealed that F8-F10 showed an increase in the dissolved sitagliptin and simvastatin to be more than 90% after 10 min.  
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Many patients with type 2 diabetes are affected by 
hypercholesterolemia. Therefore, the combination of antidiabetic and 
anti-hypercholesterolemia is appreciated as Juvisync® convenient 
tablets which are a combination of sitagliptin and simvastatin. In this 
work, sitagliptin and simvastatin rapidly dissolving tablets were 
formulated to achieve faster release than the convenient tablets and 
more suitable for elderly patients who face difficulty in swallowing. 
The literature lacks trials of the formulation of simvastatin and 
sitagliptin combination in rapidly dissolving tablets dosage form. 
There are different technologies used for manufacturing fast-
dissolving tablets, such as freeze-drying, spray-drying, tablet 
molding, sublimation, sugar-based excipients, tablet compression, 
and disintegration addition [1, 2]. In this work, simvastatin, and 
sitagliptin rapidly dissolving tablets were prepared using the easiest 
technique which is superdisintegrant addition. 
Sitagliptin phosphate monohydrate is described chemically as 7-[(3R)-
3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetra-hydro-3-
(trifluoromethyl)-1,2,4-triazolo[4,3-a] pyrazine phosphate (1:1) 
monohydrate, with the structural formula shown in fig. 1. Simvastatin 
is butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-
(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl 
ester, [1S-[1α,3α,7β,8β (2S*,4S*),-8aβ]], with the structural formula 
[3] shown in fig. 2.  
 
 
Fig. 1: Chemical structure of simvastatin 
 
Fig. 2: Chemical structure of sitagliptin phosphate monohydrate 
 
MATERIALS AND METHODS 
Materials 
Simvastatin and sitagliptin phosphate monohydrate purchased from 
Virdev, India. Explotab, microcrystalline cellulose (avicel PH 101), 
croscarmellose sodium (ac-di-sol), lactose monohydrate, magnesium 
stearate and crospovidone; kindly supplied by; Memphis 
pharmaceutical chemicals company, Cairo, Egypt. Acetonitrile for 
HPLC; Merck, Darmstadt, Germany. Hydrochloric acid, phosphoric 
acid, potassium dihydrogen phosphate; El-Nasr pharmaceutical 
chemicals company, Cairo, Egypt. High purity water was prepared by 
using a Waters Milli-Q plus purification system.  
Methodology 
Development of HPLC assays 
Two methods were developed to determine drug content of 
simvastatin and sitagliptin, dissolution rate in combination. 
Preparation of standard solution  
40 mg simvastatin and 100 mg sitagliptin were weighed accurately, 
transferred into a 100 ml measuring flask, 50 ml methanol was 
added, shaken to dissolve by sonication for 5 min, completed the 
volume with methanol and mixed well.  
International Journal of Applied Pharmaceutics 
ISSN- 0975-7058                                 Vol 10, Issue 5, 2018 
Bayoumi  
Int J App Pharm, Vol 10, Issue 5, 2018, 270-273 
271 
Preparation of test solution 
Ten tablets were weighed, and the average weight of one tablet was 
found out and ground. A weight of powdered tablet equivalent to the 
weight of one tablet was transferred into a 100 ml volumetric flask, 
about 50 ml methanol was added, sonicated for 15 min, completed the 
volume using methanol, mixed well and filtered through 0.45 µm 
membrane filter.  
Chromatographic conditions 
The separation was achieved using a Kromasil ®, USA C18 (5 μm, 25 
cm × 4.6 mm) column, Waters HPLC apparatus consisting of pump 
1525 and a UV/VIS detector 2487. The injection volume was 100 µl 
and a mobile phase consisting of acetonitrile: water 65:35 and adjust 
pH to 4 with phosphoric acid while at a flow-rate of 0.8 ml/min in 
case of simvastatin and 1.2 ml/min in case of sitagliptin which was 
detected at 266 nm while simvastatin was detected at 235 nm. 
Linearity ranges were 10–70 μg/ml and 5–30 μg/ml for sitagliptin 
and simvastatin, respectively. 
Tablets preparation 
Simvastatin and 50% of diluents were mixed and sieved using 
sieve No. 30 then kneaded with butylated hydroxyanisole 
dissolved in the least amount of alcohol. Then dried in an air oven 
till no odor of ethanol, then at a temperature not exceeding 50 ° C 
and sieved using sieve No. 30. The dried, sieved granules were 
mixed geometrically with the rest of diluent, disintegrant and 
sieved using sieve No. 30 and finally mixed with sieved lubricant 
(magnesium stearate). 
Tablets were compressed on flat punch 10 mm. All tablets were 
compressed into 330-mg using a single punch tablet machine 
[Erweka, Germany]. The force of compression was kept constant 
throughout the compression process shown in table 1. 
 
Table 1: Formulae of the rapidly dissolving simvastatin and sitagliptin tablets 
Disintegrant Diluent Formula 
Crospovidone Ac-di-sol (mg) Explotab (mg) Mannitol (mg) Avicel PH 101 (mg) 
-------- -------- 30 ------ 123.1 F 1 
-------- 30 ------ ------ 123.1 F 2 
30 -------- ------- ------ 123.1 F 3 
------ -------- 30 123.1 -------- F 4 
-------- 30 -------- 123.1 ------ F 5 
30 ------ -------- 123.1 -------- F 6 
60 -------- -------- 48.1 45 F7 
90 -------- -------- 35.1 28 F 8 
100 -------- -------- 30.1 23 F 9 
120 -------- -------- 20.1 13 F10  
 *each tablet contains 128.5 mg sitagliptin phosphate monohydrate, 40 mg simvastatin, 0.4 mg butylated hydroxyanisole, 2 mg aspartame and 6 mg 
magnesium stearate 
 
Evaluation of post-compression properties 
Weight variation 
Twenty tablets, from each formula, were individually weighed [Sartorius, 
Gottingen, Germany]. The mean weight of the tablets was calculated [4]. 
Content uniformity  
The uniformity of content was determined by crushing ten tablets 
from each formula and determining the drug content of each tablet 
individually using the developed HPLC method [4]. 
Friability  
Ten tablets of each formula were accurately weighed and placed in 
the drum of a friablator [Pharma Test, Germany], which rotated at 
25 rpm for a period of 4 min. The tablets were then brushed and 
reweighed. The percentage loss in weights was calculated and taken 
as a measure of friability [4]. 
Hardness  
Ten tablets of each formula were tested for their hardness [Tablet 
Hardness Tester, Erweka, Germany]. The mean hardness in 
kilograms was then determined [4]. 
Disintegration time  
The disintegration time for each of six tablets of each formula was 
determined using the USP disintegration tester [USP Disintegration, 
Pharma Test, Germany] [4]. 
In vitro dispersion time test  
Ten ml measuring cylinder was taken in which 6 ml distilled water 
was added then a tablet was dropped on it. The time for the tablet to 
completely disintegrate into fine particles was determined. Three 
tablets from each formulation were tested, and results were 
expressed in seconds [5, 6]. 
Wetting time 
Five circular tissue papers of 10 cm diameter were placed in a Petri 
dish with a 10 cm diameter. Ten millimeters of water-containing Eosin, 
a water-soluble dye were added to Petri dish. A tablet was carefully 
placed on the surface of the tissue paper. The time required for water 
to reach the uppermost surface of the tablet was determined [6]. 
Water absorption ratio 
A piece of tissue paper was folded twice and placed in a small Petri 
dish containing 6 ml of water. A tablet was put on the paper. The 
wetted tablet was then weighed. Water absorption ratio (R), was 
calculated by the following equation:  
)/(10 WbWaR =  
Where Wb is the weight of the tablet before water absorption and 
Wa is the weight of the tablet after water absorption [7]. 
In vitro dissolution studies 
The test was performed in 10 mm sodium phosphate buffer 
containing 1% tween 80 with 50 μg/ml butylated hydroxyanisole at 
a temperature of 37°C±0.5°C using the USP dissolution tester 
[Dissolution Apparatus Validata SR 6, Hanson Research Corporation, 
USA]. Apparatus II (paddle), at a rotation of 50 rpm [8]. Aliquots, 
each of 5 ml of the dissolution medium were withdrawn at 5, 10, 15, 
20, 30 and 45 min intervals. The samples withdrawn were then 
filtered, adequately diluted and analyzed for sitagliptin and 
simvastatin by developed HPLC assays. A similar volume of medium 
was added to the dissolution medium in order to maintain sink 
conditions, and a correction factor was included [9]. 
RESULTS AND DISCUSSION 
Formulations post-compression properties were shown in table 2. All 
formulations were evaluated for weight variation and results indicated 
very low weight variation which lies within pharmacopeia limits±5%, 
this may be due that all formula were prepared by wet granulation. 
Hardness was seen to be in the range of values of 4.3 to 6.4 kg/cm3. 
Friability of all formulae was less than 1% and the disintegration time 
of formulae tablets F8-F10 was in the range of 31 to 43 s where 
crospovidone was in percent of 27-36% of the tablet weight, which 
may be because crospovidone has been proved to result in fast volume 
expansion and hydrostatic pressures allowing tablet disintegration 
[10]. In vitro dispersion time of formulae tablets, F8-F10 was in the 
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range of 40 to 59 sec. wetting time was in the range of 48 to 130 sec. 
Water absorption ratio was in the range of 40% to 149%.  
The dissolution rate of simvastatin Q10 In comparison with the previous studies of researchers such as 
Prasanthi S, et el [12] prepared simvastatin and sitagliptin tablets by 
direct compression using pregelatinized starch and explotab as 
disintegrant, the optimized formula showed dissolution rate of 
71.25% and 69.56% for simvastatin and sitagliptin, respectively 
after 10 min while in my study the dissolution rate was more than 
90% after 10 min for both simvastatin and sitagliptin in the 
formulae F7, F8, and F9. This comparison proved that there is a 
significant improvement in my work regarding the dissolution rate. 
 from F9, F10 formulae was 
more than 90% and shown in fig. 3, this may be, because of the 
increase in the concentration of crospovidone resulted in the 
particles were exposed to dissolution medium at the comparatively 
faster rate. Also, the presence of crospovidone in the dissolution 
medium kept the drug particles in dispersed condition, i.e., 
aggregation of drug particles was avoided and also increase the 
wetting of dispersed particles due to fixation of hydrophobic drug 
particles upon hydrophilic crospovidone during the tabletting 
process resulting primarily in improvements of dissolution and 
bioavailability due to enhanced solubility [11]. 
 



















0.125±0.12 260±0.55 40±0.31 130±0.0 99.54±0.82 210±1.19 5.3±0.05 329±0.22 F1 
0.012±0.31 260±0.32 47±0.35 114±0.3 97.30±1.01 190±0.95 5.6±0.26 330±0.45 F2 
0.097±0.26 245±0.25 43±1.22 112±1.2 99.39±1.31 164±1.13 5.2±0.34 331±0.55 F3 
0.175±0.36 230±0.34 30±1.2 101±1.0 98.92±1.21 140±1.34 4.8±0.09 332±0.19 F4 
0.071±0.19 210±0.79 35±0.23 93±0.22 99.0±1.08 131±1.19 5.3±0.08 330±0.33 F5 
0.157±0.1 112±0.17 36±0.14 ±0.1481 96.96±1.28 110±1.25 5.9±0.12 329±0.6 F6 
0.089±0.16 108±0.23 71±0.51 74±0.11 98.09±1.07 90±1.13 4.3±0.15 331±0.29 F7 
0.39±0.12 59±0.42 84±0.36 61±0.22 99.60±1.33 43±0.93 5.1±0.11 329±0.6 F88 
0.084±0.25 46±0.21 140±0.12 50±0.14 100.14±0.5 32±0.22 6.1±0.21 330±0.18 F9 
0.175±0.36 40±0.17 149±0.12 48±0.22 98.09±1.07 31±0.12 6.4±0.11 332±0.18 F10 
*All values are reported as mean±standard deviation (SD), n=5. 
 
 
Fig. 3: Dissolution profile of simvastatin from prepared tablets, (All values are reported as mean±standard deviation (SD), n=6) 
 
 
Fig. 4: Dissolution profile of sitagliptin from prepared tablets, (All values are reported as mean±standard deviation (SD), n=6) 
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This study showed a new dosage form of simvastatin and sitagliptin 
which is rapidly dissolving tablets dosage form. Superdisintegrant 
addition technique using crospovidone could increase the 
dissolution of simvastatin and sitagliptin to be more than 90% after 
10 min in the formulae F 8, F 9 and F10 prepared with crospovidone 
in the range of 27-36%, while the dissolution of pure standards of 
simvastatin and sitagliptin were 12% and 30%, respectively after 10 
min showing a great enhancement in the dissolution and the 
disintegration time was less than 50 sec. 
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